FigureAsia 35 Under 35 · Healthcare
Wenhao Gao
Age 30 · Generative chemistry and synthesis planning · Stanford, United States
Co-first author of SynFormer, a 2025 system that couples molecular generation to explicit synthetic pathways and released its code, templates and weights.
- Approximate age at 31 December 2025
- 30
- Field
- Healthcare
- Country or region
- Stanford, United States
- FigureAsia U35 Assessment
- 82.9 / 100
Profile
Career and documented record
Generative chemistry has an uncomfortable failure mode: a model can propose a molecule that looks attractive in silico but offers no credible route to synthesis. Wenhao Gao's 2025 SynFormer work addressed that gap by generating molecules together with explicit synthetic pathways built from available reactions and building blocks.
Gao was a co-first author on the PNAS paper, and the team released code, reaction templates and model weights. That openness is material. It enables medicinal chemists and independent researchers to inspect how the system trades molecular objectives against synthetic reachability rather than accepting a black-box score.
The contribution remains upstream of patients. SynFormer does not establish biological activity, safety or a successful drug programme, and a feasible route in a model still requires laboratory execution. Gao's influence lies in changing the standard a generative model should meet: not merely novelty, but an actionable path from digital structure to chemical experiment. His appointment to begin an independent faculty position in 2027 is context for trajectory, not a completed impact scored in this edition.
FigureAsia selection
Why Wenhao Gao is on the list
FigureAsia selected Gao because he helped make generative drug discovery more accountable to real chemistry. Co-first authorship and an open release provide direct evidence of agency and scientific responsibility. The score reflects a high-quality enabling contribution while respecting its maturity: the value is in research infrastructure and reproducibility, not in claiming a therapy.
Verified work
The 2025–26 record
Principal milestone
Co-first-author PNAS paper in 2025
Evidence record
Code, reaction templates and model weights released
Scale or implementation
Molecules generated with explicit synthetic pathways
Field context
The work in its field
Within generative chemistry and synthesis planning, the relevant test is whether a result can survive scrutiny of maturity, attribution, validity and practical fit. That distinction matters: completed evidence is not projected benefit, and individual responsibility is not interchangeable with the wider team’s achievement.
FigureAsia U35 Assessment
Assessment breakdown
82.9out of 100
Substantive 2025–2026 contribution
18 / 20
The score reflects completed 2025–26 work in generative chemistry and synthesis planning, assessed at the documented maturity of foundational drug-discovery software.
Verified impact
10.5 / 15
Impact credit is limited to the measured study, regulatory, implementation or operating record stated in the profile; unsupported patient benefit is excluded.
Originality and distinction
9 / 10
The work creates or materially advances a distinctive capability within generative chemistry and synthesis planning rather than relying on title or institutional association.
Field and industry influence
8 / 10
The assessment recognises demonstrated effects on research, product development, care delivery or professional practice, with publicity alone carrying no weight.
Individual agency
9 / 10
Named authorship and the documented role of Postdoctoral Researcher; incoming Assistant Professor establish individual responsibility while preserving credit for collaborators.
Durability and trajectory
4.5 / 5
The cited work forms part of a continuing programme, platform or research trajectory rather than a single uncompleted announcement.
Asian significance and global relevance
4.5 / 5
The Asian connection is material to the person's identity, operating base or populations served: Chinese-educated computational chemist; undergraduate degree from Peking University.
Clinical and scientific validity
5.6 / 7
Clinical and scientific validity is calibrated to foundational drug-discovery software, with the profile retaining the evidence boundary attached to the result.
Safety, quality and responsible governance
5.6 / 7
Safety and governance credit reflects accurate regulatory language, study limitations, data stewardship and the refusal to turn early evidence into clinical certainty.
Translation and care-pathway fit
4.2 / 6
The work is scored for its demonstrated fit with a laboratory, regulatory, clinical, operational or public-health pathway, not for projected future adoption.
Access, equity and resource stewardship
4 / 5
Access credit reflects documented reach, capacity, affordability or inclusion while distinguishing service volume from proven clinical outcome.